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Bendamustine for the treatment of multiple myeloma in first-line and relapsed–refractory 
settings: a review of clinical trial data 
 
Antonio Palumbo, Massimo Offidani, Francesca Patriarca, Maria Teresa Petrucci & Michele Cavo 
Abstract 
Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal growth and/or 
dysregulation of plasma cells leading to the build-up of malignant plasma cells in the bone marrow and 
increased production of monoclonal immunoglobulins. Treatment modalities for MM include autologous 
stem cell transplant (ASCT), chemotherapy with conventional and immunomodulatory agents, radiation 
therapy and adjunct therapies. Bendamustine is a synthetic chemotherapeutic agent combining the 
alkylating properties of a mustard group with the activities of a benzimidazole ring, giving it a unique 
alkylating activity compared with other alkylating agents. Bendamustine has proven activity in both newly 
diagnosed and relapsed–refractory MM. Bendamustine has also demonstrated activity in MM after relapse 
from ASCT, and has recently been used successfully as a conditioning regimen for ASCT in combination with 
melphalan. Bendamustine is generally well tolerated, with the majority of adverse events being due to 
bone marrow suppression. Extramedullary toxicity is infrequent and usually mild. 
 
Introduction 
Multiple myeloma (MM) is a hematologic malignancy characterized by abnormal growth and/or 
dysregulation of plasma cells that leads to the build-up of malignant plasma cells in the bone marrow and 
increased production of immunoglobulins [1]. It is the second most common hematological cancer [2]: 
there were an estimated 22 350 new cases of MM in the USA in 2013, with 10 710 deaths [3]. An estimated 
750 000 people worldwide are living with MM [4]. MM is a complex disease to treat, and therapy choices 
depend on patient age, comorbidity, severity of symptoms and disease. Treatment modalities include 
autologous stem cell transplant (ASCT), chemotherapy, radiation therapy and adjunct therapies. The 
alkylating drugs cyclophosphamide and melphalan have been in clinical use for several decades [5,6]. Other 
agents which have been developed over the last 10 years for the treatment of MM include the proteasome 
inhibitor bortezomib [7], the immunomodulatory drugs thalidomide and lenalidomide [8,9] and monoclonal 
antibodies [10]. Dexamethasone and prednisolone are also used in combination with chemotherapies for 
the treatment of MM [2,11]. 
The new proteasome inhibitor carfilzomib was approved in 2012 in the USA for the treatment of patients 
who have received at least two prior therapies including bortezomib and an immunomodulatory agent 
[2,11,12]. While significant developments have been made in the treatment of MM over the past 10 years, 
the disease remains incurable, as multidrug resistance often occurs, leading to relapse and disease 
progression [13,14]. Current European Society for Medical Oncology (ESMO) treatment guidelines 
recommend melphalan plus prednisone in combination with either bortezomib or thalidomide for the 
treatment of elderly patients with advanced-stage or symptomatic MM who are ineligible for high-dose 
chemotherapy with stem cell support [15]; however, no treatment options have been developed that have 
been shown to be effective in overcoming melphalan resistance [5]. 
Bendamustine is a bifunctional alkylating agent derived from 2-chloroethylamine [16,17] which has shown 
efficacy against a number of tumor types, including hematological malignancies [1,18–20] and solid tumors 
such as small-cell lung cancer [21], breast cancer [22] and soft tissue sarcomas [23]. It has been approved in 
the USA and European Union (EU) for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin 
lymphoma refractory to rituximab, as well as for first-line treatment in follicular lymphoma in combination 
with rituximab in Switzerland [16,17], and in the EU as a first-line MM treatment, in combination with 
prednisone, in elderly patients with clinical neuropathy who are not eligible for ASCT [16,17]. In MM, the 
approved dosing is 120–150 mg/m2 bendamustine on days 1 and 2 plus 60 mg/m2 prednisone on days 1–4, 
every 4 weeks [16]. 
 
Pharmacology/pharmacokinetics/mechanism of action 
Bendamustine is a butyric acid hydrochloride/benzimidazole ring/alkylator hybrid, with the International 
Union of Pure and Applied Chemistry (IUPAC) name of 4-[5-[bis(2-chloroethyl)amino]-1-
methylbenzimidazol-2-yl] butanoic acid. It contains three structural elements: a 2-chloroethylamine 
alkylating group and a benzimidazole heterocyclic ring with a butyric acid substituent (Figure 1) [24]. The 
exact mechanism of action of bendamustine is unknown [17], but it is clear that it is different from that of 
other 2-chloroethylamine DNA-alkylating agents (e.g. chlorambucil, cyclophosphamide) [24]. The 
antineoplastic and cytocidal effect of bendamustine is due to a cross-linking of DNA single and double 
strands by alkylation. As a result, different mitotic checkpoints are inhibited, leading to induction of cell 
death by mitotic catastrophe. Bendamustine also inhibits the p53-dependent stress pathway and 
subsequently activates intrinsic apoptosis [24]. Interestingly, the active substance of bendamustine has 
little or no cross-resistance in human tumor cell lines with different resistance mechanisms, at least in part 
due to a comparatively persistent DNA interaction [16]. It is for this reason that it is believed to help 
overcome melphalan resistance [5,24]. 
 
Following an injection of bendamustine, the majority (95%) of the substance is bound to serum plasma 
proteins [16]. Bendamustine has a peak drug concentration of 11.8 μg/mL, and it takes a mean 29.6 min to 
reach this concentration [16]. The area under the concentration–time curve for bendamustine is 11.7 
μg.h/mL. Bendamustine is associated with a mean elimination half-life of 28.2 min, with a central volume of 
distribution of 19.3 L and a steady-state volume of distribution of 15.8–20.5 L. The relatively short half-life 
(t1/2) reflects the rapid metabolism and excretion of bendamustine, primarily metabolized via hydrolysis to 
metabolites with low cytotoxic activity. Active metabolites – monohydroxybendamustine and 
dihydroxybendamustine – are formed via a minor metabolic pathway involving cytochrome P450 1A2 
(CYP1A2) isoenzyme; the maximum serum concentration (Cmax) and area under the curve (AUC) for these 
metabolites are approximately 3% of the respective bendamustine values [16]. Conjugation with 
glutathione is another major route of bendamustine metabolism [16]. Potential interactions between 
bendamustine and concurrent drugs that strongly inhibit CYP1A2 (e.g. fluvoxamine, ciprofloxacin) may 
increase plasma concentrations of bendamustine, potentially increasing the risk of toxicity. Conversely, 
strong inducers of CYP1A2 (e.g. omeprazole, phenobarbital) may decrease plasma concentrations of 
bendamustine and undermine bendamustine efficacy. Bendamustine does not inhibit other cytochrome 
P450 isoenzymes, such as CYP1A4, CYP2C9/10, CYP2D6, CYP2E1 and CYP3A4 [16]. Pharmacokinetic 
parameters are not changed in patients with mild hepatic impairment (serum bilirubin < 1.2 mg/dL). 
Conversely, a dose reduction of 30% is recommended in patients with moderate hepatic impairment 
(serum bilirubin 1.2–3.0 mg/dL). Bendamustine is currently contraindicated in patients with severe hepatic 
impairment (serum bilirubin > 3.0 mg/dL). The pharmacokinetic properties of bendamustine are not 
influenced by age, or kidney function [16]. There is no evidence that dose adjustments are necessary in 
elderly patients, or in patients with creatinine clearance > 10 mL/min, although experience in patients with 
severe renal impairment is limited. Bendamustine is dialyzable. 
 
Efficacy data from clinical multiple myeloma trials 
First-line treatment 
The approval of bendamustine in the first-line indication was based on a randomized, open-label, 
multicenter, phase III study conducted by the East German Study Group of Hematology and Oncology 
(OSHO) [1]. This study compared the efficacy and tolerability of bendamustine 150 mg/m2 and melphalan 
15 mg/m2, both in combination with prednisone 60 mg/m2, in 136 adults (131 evaluable) with previously 
untreated MM aged 38–80 years (median 62 years). Both treatments were infused over 30 min: 
bendamustine on days 1 and 2 and melphalan on day 1 of a 4-week course. Treatment was continued until 
a maximum response was observed, and the primary endpoint was time to treatment failure (TTF) [1]. This 
study showed that in adults with MM, first-line combination therapy with bendamustine was significantly 
more effective than melphalan at prolonging the TTF (14 months for bendamustine therapy vs. 10 months 
for melphalan, p < 0.02) (Figure 2) [1]. Moreover, the benefits of bendamustine in terms of TTF were 
maintained beyond 30 months. Bendamustine also significantly improved the complete response (CR) rate 
(p = 0.007; Figure 3) compared with melphalan, with a maximum response achieved significantly faster in 
patients in the bendamustine treatment group (6.8 vs. 8.7 courses; p < 0.02). No significant differences in 
overall response (OR), stable (SD) and progressive disease (PD) rates (Figure 3) and median overall survival 
(OS) were observed between treatment groups [1]. 
  
Patients with renal failure 
The combination of first-line bendamustine/prednisone/bortezomib (BPV) was investigated in 18 patients 
aged 43–86 years (median 69) with MM and moderate or severe renal failure at diagnosis [25]. Patients 
received bendamustine 60 mg/m2 as a 30 min infusion on days 1 and 2, oral prednisone 100 mg on days 1, 
2, 4, 8 and 11 and intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21-day course. In patients 
who were dialysis-dependent, bendamustine and bortezomib were given 30 min after the end of dialysis. 
Treatment with BPV was continued until a maximum response, dose-limiting toxicity or disease progression 
was observed [25]. After a median of 17 months, the OS rate was 61% and progression-free survival (PFS) 
was seen in 57% of patients. The majority of patients (83.3%) responded after the first course of BPV: three 
patients had a stringent complete response (CR), five patients had a near-CR, five had a very good partial 
response (VGPR) and two had a partial response (PR) [25]. The first hematological response was observed 
after a median 14 days, and median time to best response was 42 days. The renal OR rate was 72%, and 
50% of dialysis-dependent patients became dialysis-independent [25]. These results suggest that BPV is an 
effective regimen for the first-line treatment of patients with MM with renal failure. 
Relapsed–refractory setting 
The value of bendamustine as single agent (in combination with steroids) in patients with MM with 
relapsed–refractory disease has been investigated in several retrospective observations, with response 
rates ranging between 30% and 55% [26–28]. Between April 2007 and December 2009 a French 
compassionate use program enrolled 110 patients with relapsed–refractory MM after prior therapy with 
alkylators, steroids, immunomodulators (lenalidomide or thalidomide) and bortezomib. Bendamustine was 
given at 60–150 mg/m2 on days 1 and 2 in combination with prednisone for a median of 4 (range 1–13) 28-
day courses. This program reported an OR rate of 30% in patients with relapsed–refractory MM, and after 
the cut-off day of 10 December 2010, a median duration of response had not yet been reached [26]. 
Patients had an overall median PFS of 9.3 months and OS was 12.4 months (Table I) [26]. While this was a 
retrospective study, the authors of the study believe that the 30% response rate observed in these heavily 
pretreated patients was promising, and they suggest that the results indicate that bendamustine is an 
interesting supplementary option in the armamentarium of therapeutic options for patients with relapsed–
refractory MM [26]. 
 Another retrospective analysis investigated the use of bendamustine in 39 patients treated for relapsing 
MM at a single institution in Germany over a 5-year period [27]. Patients had a median of 2 lines of prior 
therapy. Bendamustine was administered for a median of 3 (1–10) courses. Over the 5-year period, the OR 
rate to bendamustine was 36% (Table I), the median PFS was 7 months and the median OS was 17 months. 
There were no differences in remission rates between elderly and younger patients [27]. Although no 
patients achieved a CR, a PR rate of 36% meets the expected OR rate for an effective anti-myeloma agent, 
and the authors concluded that bendamustine is an effective salvage therapy option for advanced MM 
[27]. 
In 2005 Knop and colleagues [28] presented the results of a small dose-escalation study of bendamustine 
given in escalating doses (60 mg/m2 up to 100 mg/m2) in 31 patients up to age 70 years with MM 
progressing after high-dose chemotherapy. Twelve of these patients had previously received high-dose 
melphalan and six patients had undergone total marrow irradiation, busulfan and cyclophosphamide 
therapy. Patients in this study had an OR rate of 55%, with the best response rates occurring in the two 
highest-dose groups (Table I) [28]. These results further highlight the role of bendamustine as an effective 
salvage therapy option for advanced MM. 
Bendamustine in combination with other agents 
Multiple studies have investigated the use of bendamustine in combination with other therapies in the 
relapsed–refractory MM setting; although the majority of these studies were conducted in small patient 
populations, their results are still generalizable. 
Immunomodulatory agents The use of bendamustine in combination with an immunomodulatory drug 
appears to be a feasible treatment regimen for patients with relapsed–refractory MM. The combination of 
bendamustine plus thalidomide (alone or with a steroid) in patients with relapsed–refractory MM has been 
reported in three studies [29–31]. The first of these was a German multicenter trial that assessed the 
efficacy of bendamustine plus escalating doses of thalidomide plus prednisone in 28 patients who had 
received a median of 2 (1–4) prior therapies for MM [30]. Patients received bendamustine 60 mg/m2 on 
days 1, 8 and 15 in combination with oral prednisone 100 mg on days 1, 8, 15 and 22 and a dose escalation 
of thalidomide 50–200 mg/day in 28-day courses (2–10 courses total). Patients were divided into two 
groups: A, those who relapsed after standard chemotherapy; and B, those who relapsed after high-dose 
chemotherapy with stem cell support. The OR rate in these patients was 86% (Table I). No difference in 
response between groups A and B or between thalidomide dose levels was seen. Patients had an overall 
median PFS duration of 11 months and an OS duration of 19 months [30]. Between December 2008 and 
April 2010, the UK compassionate use program enrolled 23 patients with relapsed–refractory MM who 
received a median of 5 (3–7) prior therapies [29]. Bendamustine was given at 60 mg/m2 on days 1, 8 and 15 
in combination with thalidomide 50–200 mg/day and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 21 
and 22 for a median of 3 (1–6) 28-day courses. This program reported a clinical response rate (SD or greater 
response) in 61% of patients; the median PFS was 3 months, with an OS of 13 months (Table I) [29]. 
Finally, the bendamustine–thalidomide combination was also studied in a retrospective analysis of data 
from nine patients with newly diagnosed and relapsed myeloma and advanced renal disease, followed for 
up to 12 months. Findings indicated that bendamustine (120 mg on day 1) with thalidomide (100 mg/day) 
and dexamethasone (20 mg, days 1, 8, 15, and 22 of a 28-day cycle) was effective; out of nine patients, 
three achieved a CR, two a PR and two SD, while only two had PD, and the OR rate was 55%. The 
combination was well tolerated in patients with advanced renal disease due to the limited renal excretion 
of both drugs [31]. 
Two studies have reported the use of bendamustine in combination with lenalidomide [32,33]. The first of 
these studies was an open-label, phase I/II dose-escalation study investigating the efficacy of 
bendamustine/lenalidomide/dexamethasone (BLD) in patients who had received a median 3 (1–6) prior 
treatments for MM [32]. Bendamustine 75–100 mg/m2 was administered on days 1 and 2, oral 
lenalidomide 5–10 mg was administered once daily on days 1–21 and dexamethasone was administered at 
40 mg/week during the 28-day courses for a maximum of eight courses. Twenty-five patients were 
available for response, and a PR or greater occurred in 52% of them (Table I). The median PFS duration was 
6.1 months [32]. The second of these studies investigated the efficacy of 
bendamustine/lenalidomide/prednisolone (BLP) in a single-center, phase I dose-escalation study [33]. 
Patients with relapsed (first or second relapse only) or refractory MM received bendamustine 60–75 
mg/m2 on days 1 and 2, oral prednisolone 100 mg on days 1–4 and oral lenalidomide 10–25 mg once daily 
on days 1–21 of a 28-day course for a median of 2 (2–8) courses. This study showed that BLP was an 
effective treatment strategy for relapsed–refractory MM with an OR rate of 76% [33]. 
Moreover, there is a phase I/II study presented at the American Society of Hematology (ASH) 2013 meeting 
with the same combination (BLD), in which the dose of bendamustine increased from 40 to 60 mg/m2 on 
days 1–2 and lenalidomide from 15 to 25 mg for 21 days to find the maximum tolerated dose (MTD) using a 
3 + 3 cohort design. MTD was established at bendamustine 40 mg/m2 and lenalidomide 10 mg. Main grade 
3/4 adverse events were neutropenia, thrombocytopenia and anemia. With a median follow-up of 10 
months, the OR rate in 28 evaluable patients was 50% (three with CR, two with VGPR and nine with PR, and 
one with SD). The median PFS was 10 months; median OS was not reached. Phase II of the trial is ongoing 
[34]. 
Proteasome inhibitors The proteasome inhibitor bortezomib shows remarkable activity in relapsed–
refractory MM as single agent or in combination and, in vitro, was shown to enhance the sensitivity of MM 
cells to bendamustine [35]. The efficacy of the combination of bendamustine and bortezomib and a 
corticosteroid has been documented in several studies [36–41]. First, in an open-label, multicenter, non-
randomized, dose-escalating, phase I/II study in 40 patients with relapsed–refractory MM, patients 
received bendamustine plus bortezomib (Table I). This treatment regimen corresponded to an OR rate of 
48%, with an additional 43% of patients experiencing SD. Patients had a median PFS of 8.4 months and 
median OS was 13.3 months [36]. A second study investigating the efficacy of bendamustine plus 
bortezomib plus prednisone (median 2 [1–7] courses) in 78 patients with relapsed MM and either normal (n 
= 45) or restricted bone marrow function (n = 33) reported an OR rate of 69%, with no difference between 
the two patient groups (Table I). However, patients with normal bone marrow function had much better 
PFS and OS durations than those who did not (Table I) [37]. 
The activity and toxicity of bendamustine, bortezomib and dexamethasone (BVD) was investigated in a 
retrospective analysis of 50 patients with MM presenting at a single institution, treated with BVD in a 
sequential algorithm. Bortezomib was given first, followed by bortezomib plus dexamethasone if there was 
a < 25% reduction in paraprotein, and then bendamustine was added if the response was still minimal. 
Overall, seven patients received a median of 5 courses (range 1–8) of BVD. The OR rate in this study (in all 
treatment groups) was 84%, but higher partial and minimal response rates were seen in patients given BVD 
compared with the other two treatments. There were no significant differences between treatments in 
terms of PFS and OS (Table I) [39]. 
More recently, this combination has been assessed in several phase II studies, including a phase II study 
enrolling 75 patients with MM previously treated with any new drug (57% thalidomide, 54.5% 
lenalidomide, 46.5% bortezomib, 40% two new drugs). The response rate ≥ PR was 77% (20% CR, 20% 
VGPR, 37% PR) [38]. At 12 months of follow-up, median time-to-progression (TTP) was 16.5 months, PFS 
was 15.5 months and the 1-year OS was 78%. Grade 3–4 adverse events comprised 30.5% 
thrombocytopenia, 12% anemia, 18.5% neutropenia and 8% infections. Thus, the remarkable anti-myeloma 
activity of this combination was associated with manageable hematological and non-hematological toxicity 
(Table I) [38]. 
Another phase II study investigated the efficacy of four courses of BVD in 79 patients with MM, and found 
that the OR rate (CR + PR) was 60.9% (Table I). Twelve patients (15%) had a CR to treatment, 16 (20%) a 
VGPR, 20 (25.3%) a PR and 12 (15.2%) a minor response. The OR rate in patients previously exposed to 
bortezomib was 56%, the OR rate being 55% in those pretreated with lenalidomide-based regimens. 
Median time to response was 31 days (111 to best response). Median PFS and OS were 9.7 and 25.6 
months, respectively. Of note in this study, patients who had fluorescence in situ hybridization (FISH)-
defined adverse cytogenetics had comparable PFS and OS to patients who did not [40]. 
Finally, in another phase II study of BVD in 73 elderly patients (median age: 75.8 years), patients were 
initially given four courses; if they responded, two additional courses were given followed by a 
maintenance phase with six courses given every 2 months. The overall response rate was 69.8% (Table I) 
and the median PFS and OS were 10.8 and 23 months [41]. 
 
Pre-ASCT setting 
One of the mainstays of therapy for MM has been high-dose chemotherapy followed by ASCT [42,43]. Since 
the establishment of melphalan 200 mg/m2 as the standard of care conditioning regimen [42], several 
studies have attempted to optimize the conditioning regimen for ASCT in MM; however, as of yet, no 
regimen has thus far shown clear superiority to this standard without adding to toxicity [44]. A recently 
published phase I study compared different doses of bendamustine added to melphalan 200 mg/m2 daily 
in 25 patients with active MM being conditioned for ASCT. The dose-finding phase started from 
bendamustine 60 mg/m2 and reached 225 mg/m2 subdivided over 2 days without encountering a 
maximum tolerated dose. Ten patients progressed after a median of 473 days after ASCT and six patients 
died [44]. Median PFS was 791 days and the median OS was not reached, but the 2-year OS rate was 70% 
[44]. After ASCT through to 1 year of follow-up, the CR progressively improved: 40% of patients had a CR or 
better at day 30, 46% at day 60, 42% at day 100, 47% at day 180 and 48% at 1 year (Figure 4). At day 100, 
the OR rate was 79% [44]. 
 
 
Tolerability 
The most frequently reported treatment-emergent adverse events associated with bendamustine 
monotherapy are fever, allergic reactions, gastrointestinal symptoms and hematological adverse events 
[16]. Other common adverse events include infection, fatigue and mucositis, whereas extramedullary 
toxicity is infrequent and usually mild [16]. 
As first-line therapy, bendamustine was generally well tolerated when administered with prednisone, 
although more patients in the OSHO study who received bendamustine plus prednisone had severe nausea 
and vomiting compared with those who received melphalan plus prednisone (12 vs. 0) [1]. In this study, the 
tolerability profile of bendamustine was mostly consistent with the known toxicities of the agent, with 
hematological events (anemia, neutropenia, leukopenia, thrombocytopenia), nausea/vomiting and pyrexia 
the most frequently reported treatment-emergent adverse events [1]. No treatment-related adverse 
events led to treatment discontinuation [1]. Hematological adverse events (all grades) were observed in 3–
28% of bendamustine plus prednisone recipients; however, no significant differences in the incidence of 
various hematological adverse events were observed between the bendamustine plus prednisone and 
melphalan plus prednisone treatment groups (Table II) [1]. Dose reductions because of leukopenia or 
thrombocytopenia were required in 8.6% and 1.8% of patients who received bendamustine plus 
prednisone and 4.1% and 0.9% of patients who received melphalan plus prednisone [1]. 
 
When administered alone in the refractory setting, the majority of adverse events reported with 
bendamustine were mild; however, nearly all patients had at least one hematological adverse event after 
the first course of treatment (Table II), though most were grade 1/2. There was no correlation between 
dose level and hematologic toxicity [27]. 
The combinations of bendamustine with thalidomide plus dexamethasone/prednisone [29,31], with 
lenalidomide plus dexamethasone/prednisone [30], with bortezomib [36] and with bortezomib plus 
dexamethasone/prednisone (either as first-line therapy [25] or in the relapsed-refractory setting [37,38]) 
are all feasible treatment regimens with acceptable tolerability profiles. Grade 3/4 hematological adverse 
events were observed in 7–62% of bendamustine combination recipients (Table II). 
In the setting of high-dose treatment, engraftment kinetics observed with escalating bendamustine and 
melphalan conditioning were similar to those reported previously with the melphalan 200 mg/m2 
conditioning regimen. No transplant-related mortality events and no grade 3/4 non-hematological adverse 
events directly attributable to bendamustine infusion were reported [41] 
 
 
Current role of bendamustine in the treatment of myeloma 
As first-line therapy 
Clinical data for bendamustine as monotherapy or in combination with steroids and other agents show that 
this therapy is effective and well tolerated in patients with newly diagnosed MM, including patients aged 
over 65 years [1]. Currently it is registered for this indication in many European countries and South Korea, 
and in Taiwan it is in the pre-registration phase for first-line therapy. However, the role of bendamustine in 
first-line therapy of MM is not well established. 
Since MM affects a large proportion of elderly individuals, the risk/benefit profile of therapy in this 
population is very important, particularly since many of them will not be eligible for transplant [45]. The 
benefits of first-line bendamustine are shown in elderly patients; although specific age-stratified analyses 
were not performed, the population studied by Pönisch et al. was aged up to 80 years (median 62 years) 
[1]. Although bendamustine has been approved specifically in patients older than 65 years who are not 
eligible for ASCT, there are other agents also available in this setting. Standard therapies in those who are 
not candidates for ASCT are melphalan/prednisone/thalidomide, or bortezomib/melphalan/prednisone. In 
patients not able to receive melphalan due to renal impairment or other comorbidities (common in the 
elderly population), preferred treatments include thalidomide/dexamethasone, lenalidomide and 
bortezomib-based dual or triple regimens. If these cannot be used then bendamustine is an option, but its 
current role in first-line treatment of elderly patients undergoing ASCT is limited at present. 
Bendamustine is approved in combination with prednisone for first-line treatment of MM (Durie–Salmon 
stage II with progress or stage III) for patients older than 65 years who are not eligible for ASCT and who 
have clinical neuropathy at the time of diagnosis, precluding the use of thalidomide- or bortezomib-
containing treatment [16]. Studies are under way to investigate bendamustine with dexamethasone and 
carfilzomib in patients with newly diagnosed MM (NCT02002598). 
In the relapsed–refractory setting 
The clinical data for the use of bendamustine as second-line therapy in MM show clear benefits in the 
relapsed–refractory setting. Ample clinical data show that bendamustine appears to retain efficacy in 
advanced relapsed–refractory MM as monotherapy and in combination with steroids [27] and 
immunomodulatory agents, and also as part of triple therapy regimens with dexamethasone or prednisone 
plus thalidomide [29,30], lenalidomide [32,33] or bortezomib [36–40]. Triple therapy regimens have been 
shown to be more effective than dual without additional toxicity issues [27,38]. Although much of the 
evidence is from retrospective analyses and small prospective studies, particularly for monotherapy and 
dual therapy regimens, three large prospective phase II studies clearly demonstrated that the triple-therapy 
BVD is effective and well tolerated in patients with relapsed–refractory MM, including elderly patients 
[38,40,41]. The large phase II study [38] investigating BVD in patients failing up to four previous therapies, 
discussed in detail earlier in this article, showed that although outcomes were better in those with fewer 
previous therapies, OR rates of 50–60% and median TTP of 9–10 months were achieved in this difficult to 
treat population. Interestingly, a regression analysis of factors influencing TTP showed that only prior 
therapy with bortezomib/lenalidomide (and not number of prior therapies) was identified as significantly 
affecting TTP [38]. 
Phase I/II studies are also under way investigating bendamustine as part of quadruple therapy with 
bortezomib, lenalidomide and dexamethasone (NCT01484626), in triple therapy with dexamethasone and 
pomalidomide (NCT01754402) and in combination with bortezomib and pegylated liposomal doxorubicin in 
patients with relapsed–refractory MM (NCT01177683). Although not currently approved in this indication, 
bendamustine-based therapies have a role in the treatment of relapsed–refractory pretreated patients 
with advanced MM, particularly those who are known to be refractory to several available therapies. More 
data are required to confirm the place of bendamustine in advanced MM as third- or higher-line therapy. 
In elderly patients with relapsed–refractory MM, evidence shows efficacy benefits with BVD in patients 
with first relapse [41], and phase II study data revealed that patients aged over 70 years had the same TTP 
outcomes as those aged 70 or under [38]. Other studies of BVD in this population are ongoing (e.g. 
NCT01045681). 
 
Conclusions 
Bendamustine is a synthetic chemotherapeutic agent that combines the alkylating properties of a mustard 
group with the activities of a benzimidazole ring, giving it a unique alkylating activity compared with other 
alkylating agents. Bendamustine has proven activity in both newly diagnosed and in relapsed–refractory 
MM. Bendamustine has also demonstrated activity in MM after relapse from ASCT, and has recently been 
used successfully as a conditioning regimen for ASCT in combination with melphalan. Bendamustine is 
generally well tolerated, with the majority of adverse events reported with treatment due to bone marrow 
suppression. Extramedullary toxicity is infrequent and usually mild. 
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